TY - JOUR
T1 - Linking complement activation, coagulation, and neutrophils in transplant-associated thrombotic microangiopathy
AU - Gavriilaki, Eleni
AU - Chrysanthopoulou, Akrivi
AU - Sakellari, Ioanna
AU - Batsis, Ioannis
AU - Mallouri, Despina
AU - Touloumenidou, Tasoula
AU - Papalexandri, Apostolia
AU - Mitsios, Alexandros
AU - Arampatzioglou, Athanasios
AU - Ritis, Konstantinos
AU - Brodsky, Robert Alan
AU - Mitroulis, Ioannis
AU - Anagnostopoulos, Achilles
N1 - Funding Information:
E.G. was supported by the European Hematology Association Clinical Research Grant 2016. I.M. and A.C. were supported by BMBF/GSRT German-Greek Bilateral Research and Innovation Program, “BRIDGING,” grant no. T2DGED-0101. I.M. was supported by the National Center for Tumor Diseases, Dresden, Germany.
Publisher Copyright:
© 2019 Georg Thieme Verlag KG Stuttgart • New York.
PY - 2019
Y1 - 2019
N2 - Transplant-associated thrombotic microangiopathy (TA-TMA) is a severe and life-threatening complication of hematopoietic cell transplantation (HCT) that often coincides with graft-versus-host-disease (GVHD). Although endothelial damage seems to be the common denominator for both disorders, the role of complement system, neutrophils, and coagulation has not been clarified. In an effort to distinguish the pathogenesis of TA-TMA from GVHD, we evaluated markers of complement activation, neutrophil extracellular trap (NET) release, endothelial damage, and activation of coagulation cascade in the circulation of patients with these two disorders, as well as control HCT recipients without TA-TMA or GVHD. We observed that the terminal complement product C5b-9 levels, the levels of markers of NET formation, and thrombin-antithrombin complex levels were significantly increased in the TA-TMA group compared with patients without complications, whereas there was no significant difference between the GVHD and the control group. On the other hand, the levels of circulating thrombomodulin, an endothelial damage marker, were significantly increased in both TA-TMA and GVHD patients. These findings propose a role for the interplay between complement system, neutrophil activation through NET release, and activation of the coagulation cascade in TA-TMA.
AB - Transplant-associated thrombotic microangiopathy (TA-TMA) is a severe and life-threatening complication of hematopoietic cell transplantation (HCT) that often coincides with graft-versus-host-disease (GVHD). Although endothelial damage seems to be the common denominator for both disorders, the role of complement system, neutrophils, and coagulation has not been clarified. In an effort to distinguish the pathogenesis of TA-TMA from GVHD, we evaluated markers of complement activation, neutrophil extracellular trap (NET) release, endothelial damage, and activation of coagulation cascade in the circulation of patients with these two disorders, as well as control HCT recipients without TA-TMA or GVHD. We observed that the terminal complement product C5b-9 levels, the levels of markers of NET formation, and thrombin-antithrombin complex levels were significantly increased in the TA-TMA group compared with patients without complications, whereas there was no significant difference between the GVHD and the control group. On the other hand, the levels of circulating thrombomodulin, an endothelial damage marker, were significantly increased in both TA-TMA and GVHD patients. These findings propose a role for the interplay between complement system, neutrophil activation through NET release, and activation of the coagulation cascade in TA-TMA.
KW - complement
KW - graft-versus-host disease
KW - hematopoietic cell transplantation
KW - neutrophil extracellular traps
KW - thrombotic microangiopathy
UR - http://www.scopus.com/inward/record.url?scp=85071784690&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85071784690&partnerID=8YFLogxK
U2 - 10.1055/s-0039-1692721
DO - 10.1055/s-0039-1692721
M3 - Article
C2 - 31266080
AN - SCOPUS:85071784690
SN - 0340-6245
VL - 119
SP - 1433
EP - 1440
JO - Thrombosis and Haemostasis
JF - Thrombosis and Haemostasis
IS - 9
ER -